Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06176534
Status:
RECRUITING
Last Update Posted:
2023-12-19
First Post:
2023-12-09
Brief Title:
Combination Followed by Maintenance Chemotherapy Versus CDK46 Inhibitor Combined With Endocrine Therapy for HR LowHER2-negative Advanced Breast Cancer a Prospective Randomized Open-label Phase Ⅱ Clinical Trial
Sponsor:
Henan Cancer Hospital
Organization:
Henan Cancer Hospital
Study Overview
Official Title:
Combination Followed by Maintenance Chemotherapy Versus CDK46 Inhibitor Combined With Endocrine Therapy for HR LowHER2-negative Advanced Breast Cancer a Prospective Randomized Open-label Phase Ⅱ Clinical Trial
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To observe the differences in the efficacy of Combination followed by maintenance chemotherapy versus CDK46 inhibitor combined with endocrine therapy in HR low expression HER2 negative advanced breast cancer and to provide new evidence for the best treatment of HR low expression HER2 negative advanced breast cancer and to explore the efficacy and safety of combinedmaintenance chemotherapy
Detailed Description:
To observe the differences in the efficacy of Combination followed by maintenance chemotherapy versus CDK46 inhibitor combined with endocrine therapy in HR low expression HER2 negative advanced breast cancer and to provide new evidence for the best treatment of HR low expression HER2 negative advanced breast cancer and to explore the efficacy and safety of combinedmaintenance chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None